LianBio announces the price of its initial public offering

SHANGHAI, China and PRINCETON, NJ, October 31, 2021 (GLOBE NEWSWIRE) – LianBio, a biotechnology company dedicated to delivering innovative medicines to patients in China and other major Asian markets, today announced the award of its initial public offering of 20,312,500 US Depositary Shares (“ADS”) at a public offering price of $ 16.00 per ADS, for gross proceeds of approximately $ 325.0 million, before deduction of discounts and subscription fees and offering fees. Each ADS represents one ordinary share of LianBio, and all ADSs are offered by LianBio. In addition, LianBio has granted subscribers a 30-day option to purchase up to an additional 3,046,875 ADSs at the initial public offering price, less subscription discounts and commissions.

The ADSs are expected to begin trading on the Nasdaq Global Market on November 1, 2021 under the ticker symbol “LIAN”, and the offer is expected to close on November 3, 2021, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Jefferies LLC and BofA Securities, Inc. are acting as co-book managers for the offering. Raymond James acts as the leader of the offer.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective October 29, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, can be obtained from: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, Jefferies LLC, Attn: Equity Syndicate Prospectus Department , 520 Madison Avenue, 2nd Floor, New York, New York 10022, by phone at (877) 821-7388 or by email at [email protected], and BofA Securities, Inc., Attn: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC, 28255-0001 or by email at [email protected]

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be. illegal before registration or qualification. under the securities laws of any such state or jurisdiction.

About LianBio

LianBio is a cross-border biotechnology company with a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is developing a diverse portfolio of clinically validated product candidates with the potential to drive new standards of care in cardiovascular, oncology, ophthalmology, inflammatory and respiratory indications. LianBio is building an international infrastructure to position the company as a partner of choice with a platform to access China and other Asian markets.

Caution Regarding Forward-Looking Statements

Statements in this press release regarding future expectations, plans and prospects, as well as any other statements regarding matters which are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. from 1995. These statements include statements relating to the commencement of trading and the expected closing date of the offer. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend to”, “can”, “should”, “target”, “Will”, “should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated in these forward-looking statements due to various important factors, including: uncertainties relating to market conditions and the completion of the initial public offering under expected conditions or not at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date hereof, and LianBio specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not trust any information on this page to be current or accurate after the date of publication.

For investor inquiries, please contact:
Elizabeth Anderson, Vice President of Communications and Investor Relations
E: [email protected]
Phone. : +1 646 655 8390

For media inquiries, please contact:
Katherine Smith, CanaleComm
E: [email protected]
T: +1 619 849 5378

About Michael Bill

Check Also

Rapid Influenza Diagnostics Market Indication by Industry Dynamics, Regional Breakdown and Forecast 2022-2027 – The Daily Vale

New York, United States: the Rapid Influenza Diagnostics Market research report written by DECISIVE MARKET …

Leave a Reply

Your email address will not be published.